Over recent years, A&M has seen incredible growth in France. As the year ends, we look back at the success of 2021 and development the firm has seen within the French team.
The Paris-based team has grown from just over 30 people in 2018 to now over 130, demonstrating a growth of over 300% in three years. In 2021 alone, A&M France welcomed four new Managing Directors and introduced two new sector offerings to expand the breadth and depth of what the team can offer French clients and businesses.
2022 is off to a great start with the launch of A&M Digital EMEA, led by Jean-Laurent Poitou. Based in Paris, he will lead the development of a fully integrated digital offering in EMEA to deliver tangible business results for our clients. His joining marks the next phase of growth for A&M within France as the team continues to grow to meet client demand.
To read the full report, click here.
.
Digital Deception: Fighting Fraud in the Era of Emerging Technology
August 26, 2025
Davin Teo and Henry Chambers, Managing Directors and Co-leaders of Disputes and Investigations Asia wrote an article on digital deception for the Hong Kong Chartered Governance Institute’s CGj August 2025 issue.
Unlocking Federal Real Estate: Efficiency, Partnerships, and the Path Ahead
August 26, 2025
Managing Director Tom Scott and Senior Director Paul Firth, join George Guszcza, President & CEO of the National Institute of Building Sciences, on The GovNavigators Show to discuss trends, challenges, and opportunities shaping the future of federal real estate.
DOJ and HHS collaborate to enhance False Claims Act prosecution
August 25, 2025
In a recent article for Westlaw Today, Managing Directors Jenelle Beavers and Donald Lochabay explore the U.S. government’s new collaboration and enforcement priorities around the False Claims Act (FCA).
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
